Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis

It remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhale...

Full description

Bibliographic Details
Published in:Antibiotics
Main Authors: Sofia Tejada, Sergio Ramírez-Estrada, Carlos G. Forero, Miguel Gallego, Joan B. Soriano, Pablo A. Cardinal-Fernández, Stephan Ehrmann, Jordi Rello
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Subjects:
Online Access:https://www.mdpi.com/2079-6382/11/2/275
_version_ 1850383606356115456
author Sofia Tejada
Sergio Ramírez-Estrada
Carlos G. Forero
Miguel Gallego
Joan B. Soriano
Pablo A. Cardinal-Fernández
Stephan Ehrmann
Jordi Rello
author_facet Sofia Tejada
Sergio Ramírez-Estrada
Carlos G. Forero
Miguel Gallego
Joan B. Soriano
Pablo A. Cardinal-Fernández
Stephan Ehrmann
Jordi Rello
author_sort Sofia Tejada
collection DOAJ
container_title Antibiotics
description It remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhaler (DPI) and via nebulizers (SVN) among adult patients with NCFB. Inclusion criteria were randomized-controlled trials, adults (≥18 years) with NCFB, and inhaled antibiotics administered via DPI as intervention. Search strategy was performed in PubMed, Web of Science, and Cochrane Library from 2000 to 2019. Sixteen trials (2870 patients) were included. Three trials (all ciprofloxacin) used DPIs and thirteen used SVN (three ciprofloxacin). Both DPI and SVN devices achieved similar safety outcomes (adverse events, antibiotic discontinuation, severe adverse events, and bronchospasm). Administration of ciprofloxacin via DPI significantly improved time to first exacerbation (87 days, 95% CI 34.3–139.7) and quality of life (MD −7.52; 95% CI −13.06 to −1.98) when compared with via SVN. No other significant differences were documented in clinical efficacy (at least one exacerbation, FEV<sub>1</sub>% predicted) and microbiologic response (bacterial eradication, emergence of new potential pathogens, and emergence of antimicrobial resistance) when comparing devices. Our NMA documented that time to first exacerbation and quality of life, were more favorable for DPIs. Decisions on the choice of devices should incorporate these findings plus other criteria, such as simplicity, costs or maintenance requirements.
format Article
id doaj-art-468b096d2e384c7ea6470acede4a2e85
institution Directory of Open Access Journals
issn 2079-6382
language English
publishDate 2022-02-01
publisher MDPI AG
record_format Article
spelling doaj-art-468b096d2e384c7ea6470acede4a2e852025-08-19T22:56:26ZengMDPI AGAntibiotics2079-63822022-02-0111227510.3390/antibiotics11020275Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-AnalysisSofia Tejada0Sergio Ramírez-Estrada1Carlos G. Forero2Miguel Gallego3Joan B. Soriano4Pablo A. Cardinal-Fernández5Stephan Ehrmann6Jordi Rello7Clinical Research/Epidemiology in Pneumonia & Sepsis (CRIPS), Vall d’Hebron Institut of Research (VHIR), 08035 Barcelona, SpainIntensive Care Department, Clínica Corachán, 08017 Barcelona, SpainSchool of Medicine, Universitat Internacional de Catalunya, 08195 Barcelona, SpainCentro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, SpainCentro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, SpainIntensive Care Unit, HM Group, 28015 Madrid, SpainCHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSEP F-CRIN Research Network, 37000 Tours, FranceClinical Research/Epidemiology in Pneumonia & Sepsis (CRIPS), Vall d’Hebron Institut of Research (VHIR), 08035 Barcelona, SpainIt remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhaler (DPI) and via nebulizers (SVN) among adult patients with NCFB. Inclusion criteria were randomized-controlled trials, adults (≥18 years) with NCFB, and inhaled antibiotics administered via DPI as intervention. Search strategy was performed in PubMed, Web of Science, and Cochrane Library from 2000 to 2019. Sixteen trials (2870 patients) were included. Three trials (all ciprofloxacin) used DPIs and thirteen used SVN (three ciprofloxacin). Both DPI and SVN devices achieved similar safety outcomes (adverse events, antibiotic discontinuation, severe adverse events, and bronchospasm). Administration of ciprofloxacin via DPI significantly improved time to first exacerbation (87 days, 95% CI 34.3–139.7) and quality of life (MD −7.52; 95% CI −13.06 to −1.98) when compared with via SVN. No other significant differences were documented in clinical efficacy (at least one exacerbation, FEV<sub>1</sub>% predicted) and microbiologic response (bacterial eradication, emergence of new potential pathogens, and emergence of antimicrobial resistance) when comparing devices. Our NMA documented that time to first exacerbation and quality of life, were more favorable for DPIs. Decisions on the choice of devices should incorporate these findings plus other criteria, such as simplicity, costs or maintenance requirements.https://www.mdpi.com/2079-6382/11/2/275bronchiectasisnon-cystic fibrosisdry powder inhaledsmall-volume nebulizerinhaled antibiotics
spellingShingle Sofia Tejada
Sergio Ramírez-Estrada
Carlos G. Forero
Miguel Gallego
Joan B. Soriano
Pablo A. Cardinal-Fernández
Stephan Ehrmann
Jordi Rello
Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
bronchiectasis
non-cystic fibrosis
dry powder inhaled
small-volume nebulizer
inhaled antibiotics
title Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
title_full Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
title_fullStr Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
title_full_unstemmed Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
title_short Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
title_sort safety and efficacy of devices delivering inhaled antibiotics among adults with non cystic fibrosis bronchiectasis a systematic review and a network meta analysis
topic bronchiectasis
non-cystic fibrosis
dry powder inhaled
small-volume nebulizer
inhaled antibiotics
url https://www.mdpi.com/2079-6382/11/2/275
work_keys_str_mv AT sofiatejada safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT sergioramirezestrada safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT carlosgforero safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT miguelgallego safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT joanbsoriano safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT pabloacardinalfernandez safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT stephanehrmann safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis
AT jordirello safetyandefficacyofdevicesdeliveringinhaledantibioticsamongadultswithnoncysticfibrosisbronchiectasisasystematicreviewandanetworkmetaanalysis